Research context. GHRP-2 is a synthetic growth-hormone-releasing peptide used to investigate ghrelin/growth-hormone secretagogue receptor activity. Findings from experimental models do not establish clinical safety or efficacy.
GHRP-2 — Technical Research Profile
| Research classification |
Synthetic growth-hormone secretagogue hexapeptide |
| Available size(s) |
5MG |
| Primary research system |
Ghrelin/growth-hormone secretagogue receptor 1a (GHSR1a) |
Molecular and structural context
GHRP-2 is a compact synthetic hexapeptide incorporating non-natural residues that improve receptor activity and proteolytic stability. Its sequence is structurally unrelated to endogenous ghrelin despite converging on the same receptor system.
Mechanistic research framework
GHSR1a is a GPCR with notable constitutive activity and predominant Gq/11 coupling. Ligand stimulation can activate phospholipase C, inositol-phosphate formation, intracellular calcium mobilization, and downstream endocrine signalling.
It is applied in receptor-response, endocrine secretion, dose-response, and signalling-selectivity experiments.
Experimental applications and endpoint selection
Cell-based research may quantify calcium flux, IP1 accumulation, beta-arrestin recruitment, receptor internalization, constitutive activity, and concentration-response behavior. Ghrelin and receptor antagonists can serve as mechanistic comparators.
This material is intended for analytical, biochemical, receptor-pharmacology, cellular, or other controlled preclinical workflows as appropriate to the target system. Study design should define the biological matrix, exposure duration, concentration range, replicate structure, acceptance criteria, and statistical plan before data collection.
Principal areas of scientific inquiry
- GHSR receptor activation
- Endocrine secretion models
- Peptide dose-response research
Technical keywords
- GHSR1a agonism
- Calcium mobilization
- Constitutive receptor activity
- Secretagogue pharmacology
Analytical characterization considerations
Stereochemical integrity and sequence-related impurities are important for short secretagogue peptides. LC-MS, RP-HPLC, and receptor-based potency assays can help distinguish chemical purity from functional activity.
Where scientifically appropriate, laboratories may use orthogonal methods such as reversed-phase HPLC for chromatographic purity, LC-MS for molecular identity, size-sensitive methods for aggregation, and a target-relevant functional assay for biological activity. Method suitability, reference standards, system suitability, and acceptance limits must be independently established; these examples are not batch-specific analytical claims.
Study design and interpretation
Use vehicle, positive, negative, and concentration-matched controls appropriate to the assay. Receptor expression, biological matrix, incubation time, adsorption, proteolysis, passage number, and species background can all change apparent potency or pathway output. Observations from in vitro or animal models should not be extrapolated to human use.
Handling and documentation
Use calibrated equipment and documented receipt, storage, preparation, aliquoting, freeze-thaw, and disposal procedures. Solvent compatibility, working concentration, stability window, container adsorption, and assay recovery must be established by the purchasing laboratory using the applicable batch documentation and institutional standard operating procedures.
Important compliance and safety remarks
- No therapeutic, diagnostic, cosmetic, or veterinary claims are made.
- Work must be performed by qualified personnel under applicable institutional and regulatory requirements.
- Use appropriate personal protective equipment and controlled laboratory procedures.
For research use only. Not for human or animal consumption.
Research-use notice. This material is supplied solely for legitimate research and analytical purposes. Researchers are responsible for material suitability, laboratory safety, and compliance with all applicable requirements.
